Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | DM Peereboom, LB Nabors, P Kumthekar, MA Badruddoja, KL Fink, FS Lieberman, S Phuphanich, EM Dunbar, T Walbert, D Schiff, DD Tran, LS Ashby, NA. Butowski, FM Iwamoto, R Lindsay, J Bullington, M Schulder, J Sherman, T Goswami, DA. Reardon | ||||||||||||
Title | Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival. | ||||||||||||
|
|||||||||||||
URL | http://abstracts.asco.org/214/AbstView_214_229695.html | ||||||||||||
Abstract Text | J Clin Oncol 36, 2018 (suppl; abstr 2058) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SL-701 | SL 701|SL701 | SL-701 is an immunotherapy that stimulates anti-tumor immune responses against tumor expressing IL13 receptor alpha-2, EphrinA2 and Survivin (J Clin Oncol 36, 2018 (suppl; abstr 2058)). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|